Role of caffeine in slowing progression of myopia: 1-year results from a prospective, longitudinal clinical trial.

Purpose: To determine the role of topical caffeine in slowing progression of myopia, both as a standalone treatment and in combination with atropine.

Methods: In a prospective, randomized, dispensing clinical trial, 96 children with myopia, aged 6-13 years, spherical equivalent (SE) from -0.50 diopters (D) to -6.

Impact of Various Concentrations of Low-Dose Atropine on Pupillary Diameter and Accommodative Amplitude in Children with Myopia.

To assess over 2 weeks, the effect of 3 different low concentrations of atropine on pupillary diameter and accommodative amplitude in children with myopia. Fifty-eight children with myopia [spherical equivalent (SE) of -0.50 diopters (D) or worse, astigmatism of less than or equal to 2.

A Meta-Analysis Assessing Change in Pupillary Diameter, Accommodative Amplitude, and Efficacy of Atropine for Myopia Control.

Purpose: To determine the effect of atropine on pupillary diameter, accommodative amplitude as well as myopia progression.

Methods: Medical databases and Cochrane Library were systematically searched for studies from 1980 until June 2020. The primary and secondary outcomes were: a) change in pupillary diameter (PD) and accommodative amplitude (AA) and b) annualized mean change in spherical equivalent and axial length with various concentrations of atropine compared to control.